Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01286012 · ClinicalTrials.gov registry record · Phase 2
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
A Phase 2 study, sponsored by Rockwell Medical Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT01286012 is a Phase 2 study that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 108 participants.
The verdict
NCT01286012, a Phase 2 study, has completed, sponsored by Rockwell Medical Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb) levels in chronic hemodialysis subjects who receive SFP via the dialysate versus subjects who receive conventional dialysate without iron.
Interventions
- DRUG Soluble Ferric Pyrophosphate in liquid bicarbonate
- DRUG Placebo: Conventional liquid bicarbonate
- DRUG Erythrocyte Stimulating Agent (ESA)
- DRUG Intravenous (IV) Iron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01286012
The ClinicalTrials.gov registry entry for NCT01286012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Soluble Ferric Pyrophosphate in liquid bicarbonate is the first listed.
NCT01286012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01286012 about?
NCT01286012 is a clinical study titled "Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients". The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb) levels in chronic hemodialysis subjects who receive SFP via the dialysate versus subjects who receive conventional di...
What is the current status of trial NCT01286012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2011-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01286012?
The interventions under investigation include: Soluble Ferric Pyrophosphate in liquid bicarbonate (DRUG), Placebo: Conventional liquid bicarbonate (DRUG), Erythrocyte Stimulating Agent (ESA) (DRUG), Intravenous (IV) Iron (DRUG).
Who is sponsoring clinical trial NCT01286012?
This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.